tbuckley/cabot-search huggingface dataset:
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)
Authors: Kathy D. Miller, Anne O’Neill, William Gradishar, Timothy J. Hobday, Lori J. Goldstein, Ingrid A. Mayer, Stuart Bloom, Adam M. Brufsky, Amye J. Tevaarwerk, Joseph A. Sparano, Nguyet Anh Le-Lindqwister, Carolyn B. Hendricks, Donald W. Northfelt, Chau T. Dang, George W. Sledge
Journal: Journal of Clinical Oncology (2018)

Purpose Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2–negative disease. Patients and Methods Patients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel (arm B), or bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C). Random assignment was stratified and bevacizumab dose adjusted for choice of AC schedule. Radiation and hormonal therapy were administered concurrently with bevacizumab in arm C. The primary end point was invasive disease–free survival (IDFS). Results Four thousand nine hundred ninety-four patients were enrolled. Median age was 52 years; 64% of patients were estrogen receptor positive, 27% were lymph node negative, and 78% received dose-dense AC. Chemotherapy-associated adverse events including myelosuppression and neuropathy were similar across all arms. Grade ≥ 3 hypertension was more common in bevacizumab-treated patients, but thrombosis, proteinuria, and hemorrhage were not. The cumulative incidence of clinical congestive heart failure at 15 months was 1.0%, 1.9%, and 3.0% in arms A, B, and C, respectively. Bevacizumab exposure was less than anticipated, with approximately 24% of patients in arm B and approximately 55% of patients in arm C discontinuing bevacizumab before completing planned therapy. Five-year IDFS was 77% (95% CI, 71% to 81%) in arm A, 76% (95% CI, 72% to 80%) in arm B, and 80% (95% CI, 77% to 83%) in arm C. Conclusion Incorporation of bevacizumab into sequential anthracycline- and taxane-containing adjuvant therapy does not improve IDFS or overall survival in patients with high-risk human epidermal growth factor receptor 2–negative breast cancer. Longer duration bevacizumab therapy is unlikely to be feasible given the high rate of early discontinuation.
Methodological Recommendations for Trials of Psychological Interventions
Authors: Jenny Guidi, Eva-Lotta Brakemeier, Claudi L.H. Bockting, Fiammetta Cosci, Pim Cuijpers, Robin B. Jarrett, Michael Linden, Isaac Marks, Charles S. Peretti, Chiara Rafanelli, Winfried Rief, Silvia Schneider, Ulrich Schnyder, Tom Sensky, Elena Tomba, Carmelo Vazquez, Eduard Vieta, Stephan Zipfel, Jesse H. Wright, Giovanni A. Fava
Journal: Psychotherapy and Psychosomatics (2018)

Recent years have seen major developments in psychotherapy research that suggest the need to address critical methodological issues. These recommendations, developed by an international group of researchers, do not replace those for randomized controlled trials, but rather supplement strategies that need to be taken into account when considering psychological treatments. The limitations of traditional taxonomy and assessment methods are outlined, with suggestions for consideration of staging methods. Active psychotherapy control groups are recommended, and adaptive and dismantling study designs offer important opportunities. The treatments that are used, and particularly their specific ingredients, need to be described in detail for both the experimental and the control groups. Assessment should be performed blind before and after treatment and at long-term follow-up. A combination of observer- and self-rated measures is recommended. Side effects of psychotherapy should be evaluated using appropriate methods. Finally, the number of participants who deteriorate after treatment should be noted according to the methods that were used to define response or remission.
Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome
Authors: Jane M. Natividad, Allison Agus, Julien Planchais, Bruno Lamas, Anne Charlotte Jarry, Rebeca Martin, Marie-Laure Michel, Caroline Chong-Nguyen, Ronan Roussel, Marjolene Straube, Sarah Jegou, Claire McQuitty, Maude Le Gall, Gregory da Costa, Emmanuelle Lecornet, Chloé Michaudel, Morgane Modoux, Jeremy Glodt, Chantal Bridonneau, Bruno Sovran, Louise Dupraz, Andre Bado, Mathias L. Richard, Philippe Langella, Boris Hansel, Jean-Marie Launay, Ramnik J. Xavier, Henri Duboc, Harry Sokol
Journal: Cell Metabolism (2018)
Electromagnetic Versus Fluoroscopic Mapping of the Inferior Isthmus for Ablation of Typical Atrial Flutter
Authors: HansKottkamp, BurkhardtHügl, BeateKrauss, UlrikeWetzel, AnneFleck, GerhardSchuler, GerhardHindricks
Journal: Circulation (2000)

Background—Radiofrequency catheter ablation within the tricuspid annulus–inferior caval vein isthmus can cure typical atrial flutter. The target for ablation, nonetheless, is relatively wide, and standard ablation procedures may require significant exposure to radiation. Methods and Results—A total of 50 patients (mean age, 58±11 years) with typical atrial flutter were prospectively randomized to receive isthmus ablation using conventional fluoroscopy for catheter navigation (group I, n=24) or electromagnetic mapping (group II, n=26). Complete bidirectional isthmus block was verified with double potential mapping. If complete isthmus block could not be achieved after 20 radiofrequency pulses or 25 minutes of fluoroscopy, the patients were switched to the other group. Eight patients from group I (33%) but only 1 patient from group II (4%) were switched. Overall, complete isthmus block was achieved in 47 of 50 patients (94%). The overall fluoroscopy time, including the placement of the diagnostic catheters,...
Erratum: “Climate Change and Future Pollen Allergy in Europe”
Authors: Iain R. Lake, Natalia R. Jones, Maureen Agnew, Clare M. Goodess, Filippo Giorgi, Lynda Hamaoui-Laguel, Mikhail A. Semenov, Fabien Solmon, Jonathan Storkey, Robert Vautard, Michelle M. Epstein
Journal: Environmental Health Perspectives (2018)

[This corrects the article DOI: 10.1289/EHP173.].
Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid/rhabdoid tumor
Authors: Johannes Nowak, Karolina Nemes, Annika Hohm, Lindsey A Vandergrift, Martin Hasselblatt, Pascal D Johann, Marcel Kool, Michael C Frühwald, Monika Warmuth-Metz
Journal: Neuro-Oncology (2018)

Recently, 3 molecular subgroups of atypical teratoid/rhabdoid tumor (ATRT) were identified, but little is known of their clinical and magnetic resonance imaging (MRI) characteristics. A total of 43 patients with known molecular subgroup status (ATRT–sonic hedgehog [SHH], n = 17; ATRT-tyrosine [TYR], n = 16; ATRT–myelocytomatosis oncogene [MYC], n = 10) were retrieved from the EU-RHAB Registry and analyzed for clinical and MRI features. On MRI review, differences in preferential tumor location were confirmed, with ATRT-TYR being predominantly located infratentorially (P < 0.05). Peritumoral edema was more pronounced in ATRT-MYC compared with ATRT-SHH (P < 0.05) and ATRT-TYR (P < 0.05). Conversely, peripheral tumor cysts were found more frequently in ATRT-SHH (71%) and ATRT-TYR (94%) compared with ATRT-MYC (40%, P < 0.05). Contrast enhancement was absent in 29% of ATRT-SHH (0% of ATRT-TYR; 10% of ATRT-MYC; P < 0.05), and there was a trend toward strong contrast enhancement in ATRT-TYR and ATRT-MYC. We found the characteristic (bandlike) enhancement in 28% of ATRT as well as restricted diffusion in the majority of tumors. A midline/off-midline location in the posterior fossa was also not subgroup specific. Visible meningeal spread (M2) at diagnosis was rare throughout all subgroups. These exploratory findings suggest that MRI features vary across the 3 molecular subgroups of ATRT. Within future prospective trials, MRI may aid diagnosis and treatment stratification.
Intra-hospital mortality for community-acquired pneumonia in mainland Portugal between 2000 and 2009
Authors: F. Teixeira-Lopes, A. Cysneiros, A. Dias, V. Durão, C. Costa, F. Paula, M. Serrado, B. Nunes, A. Diniz, F. Froes
Journal: Pulmonology (2018)

Community-acquired pneumonia (CAP) remains a common and serious infection with wide variability in intra-hospital mortality. We performed a retrospective analysis of adult patients admitted with CAP in mainland Portugal between the years 2000 and 2009. The intra-hospital mortality rate was 20.4% with deaths in all age groups. The average age of deceased patients was 79.8 years, significantly higher than surviving patients with 71.3 years. Patients aged 50 or more presented a relative risk of death 4.4 times the risk of patients under this age group. Likewise, in patients aged 65 or more the risk of death was 3.2 times the risk of patients <65 years. Men died more at a younger age than women, the men who died were, on average, 4 years younger than women, 78.1 vs 82.1 years old. Relative risk of death in men was 17% higher than women after adjustment for year of admission and age. CAP remains an important cause of hospital mortality in all age groups.
Brain-computer interfaces for stroke rehabilitation: summary of the 2016 BCI Meeting in Asilomar
Authors: Christoph Guger, José del R. Millán, Donatella Mattia, Junichi Ushiba, Surjo R. Soekadar, Vivek Prabhakaran, Natalie Mrachacz-Kersting, Kyousuke Kamada, Brendan Z. Allison
Journal: Brain-Computer Interfaces (2018)

Brain-computer interfaces (BCIs) based on motor imagery have been gaining attention as tools to facilitate recovery from movement disorders resulting from stroke or other causes. These BCIs can detect imagined movements that are typically required within conventional rehabilitation therapy. This information about the timing, intensity, and location of imagined movements can help assess compliance and control feedback mechanisms such as functional electrical stimulation (FES) and virtual avatars. Here, we review work from eight groups that each presented recent results with BCI-based rehabilitation at a workshop during the 6th International Brain-Computer Interface Meeting. We also present major directions and challenges for future research.
A pilot feasibility study of definitive concurrent chemoradiation with pencil beam scanning proton beam in combination with 5-fluorouracil and mitomycin-c for carcinoma of the anal canal.
Authors: Jennifer Yon-Li Wo, Beow Y. Yeap, Thomas F. DeLaney, David P. Ryan, Aparna Raj Parikh, Jeffrey W. Clark, Jill N. Allen, Edgar Ben-Josef, John Peter Plastaras, James M. Metz, Lorraine C. Drapek, Theodore S. Hong
Journal: Journal of Clinical Oncology (2018)

733 Background: Definitive chemoradiation (CRT) with concurrent 5-fluorouracil (5-FU)/mitomycin C (MMC) for anal cancer yields high rates of long term survival. However, CRT has significant acute and long term toxicity. Pencil beam scanning proton beam (PBS-PT) may potentially reduce this toxicity. This is a pilot study evaluating the feasibility of definitive concurrent CRT with PBS-PT with 5-FU/MMC for anal cancer. Methods: Pts were enrolled on an NCI sponsored, prospective, multi-institutional, pilot study (NCT 01858025). Key eligibility were ECOG 0-2, age 18+, invasive SCC of the anal canal, clinically staged T1-4, N0-3. Pts were treated per RTOG 0529 RT schema; for T1-2, N0: 50.4 Gy to primary CTV, 42 Gy to elective LNs; for T3+ or N+: 54 Gy to primary CTV, 50.4-54 Gy to involved LN, and 45 Gy to elective LNs. Pts received 5-FU/MMC on day 1 and 29. The primary objective of this study was to determine feasibility of PBS-PT with 5-FU/MMC, determined if grade 3+ dermatologic toxicity is &lt; 48% (grade 3+ dermatologic toxicity from RTOG 98-11). The secondary endpoint was rates of overall grade 3+ toxicities, clinical complete response (cCR) rate and patterns of local regional tumor recurrence. Results: Between February 2014 to April 2017, we enrolled 25 patients into our study, all of whom were analyzed. 23 pts (92%) completed treatment per protocol, 2 pts died on treatment due to underlying comorbidities. Median time to completion of treatment was 42 days (range 38-49). The Grade 3+ radiation dermatitis was 24% (Table 1). With a median follow-up of 17.6 months (range 7.7-42.0) among the 21 patients still alive, the 1 year local control, progression-free survival, and overall survival are 100%, 83% and 87%, respectively. Conclusions: In our prospective, pilot study of PBS-PT with concurrent 5-FU/MMC, PBS-PT was found to be feasible. While felt to be unrelated to the study, the two Grade 5 adverse events on this small study highlights potentially treatment related risks of this effective yet toxic regimen. Clinical trial information: NCT01858025. [Table: see text]
Adiponectin Inhibits Endothelial Synthesis of Interleukin-8
Authors: ChikaakiKobashi, MasaharuUrakaze, MikaKishida, EtsukoKibayashi, HidekiKobayashi, ShinjiKihara, TohruFunahashi, MichiyoTakata, RieTemaru, AkiraSato, KatsuyaYamazaki, NorioNakamura, MasashiKobayashi
Journal: Circulation Research (2005)

Adiponectin is an antiatherogenic adipokine that inhibits inflammation by mechanisms that are not completely understood. We explored the effect of adiponectin on endothelial synthesis of interleukin-8 (IL-8), a pro-inflammatory chemokine that plays a role in atherogenesis. Adiponectin decreased the secretion of IL-8 from human aortic endothelial cells (HAEC) stimulated with tumor necrosis factor-α (TNF-α). Adiponectin also inhibited IL-8 mRNA expression induced by TNF-α. Phosphorylation of IκB-α was decreased by adiponectin, but phosphorylation of ERK, SAPK/JNK, and p38MAPK were unaffected. Adiponectin increased intra-cellular cAMP levels in HAEC in a dose-dependent manner; PKA activity was also increased. The inhibitory effect of adiponectin on TNF-α–induced IL-8 synthesis was inhibited by pretreatment with Rp-cAMP, a PKA inhibitor. These observations suggest that adiponectin inhibits IL-8 synthesis through inhibition of a PKA dependent NF-κB signaling pathway. We also showed that adiponectin enhances Ak...
A New Dark Skin Lesion in a 3-Year-Old Undergoing Induction Therapy for Acute Lymphoblastic Leukemia
Authors: Andrew M. Armenta, Paul R. Massey, Lucia Z. Diaz
Journal: JAMA Oncology (2018)

A 3-year-old girl with B-cell acute lymphoblastic leukemia and no known skin trauma presented with an asymptomatic skin lesion with violaceous to black plaque, a central hemorrhagic bulla, and surrounding hyperemia on the left lower back. What is your diagnosis?
Common Issues in the Unique Environment of Global Surgical Health Services Research
Authors: Arden M. Morris, Clara Nan-hi Lee
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract 13921: Macrophage Polarization in Epicardial Adipose Tissue is Correlated with Severity of Human Coronary Artery Disease
Authors: Yoichiro Hirata, Tatsuo Motoki, Hirotsugu Kurobe, Masashi Akaike, Minoru Tabata, Shuichiro Takanashi, Takashi Igarashi, Tetsuya Kitagawa, Masataka Sata
Journal: Circulation (2010)
Abstract 3917: Role of Endothelial Cell-Selective Adhesion Molecule in the Progression of Atherosclerosis
Authors: Michihiko Inoue, Tatsuro Ishida, Tetsuya Hara, Cangara M Husni, Li Sun, Ken-ichi Hirata
Journal: Circulation (2008)

Backgrounds : Endothelial cell-selective adhesion molecule (ESAM) is a new member of the immunoglobulin superfamily, which is expressed in vascular endothelial cells. Although ESAM has been shown to mediate homohilic adhesion between endothelial cells, the interaction of ESAM and hematopoietic cells has not been ingestigated. Also, the role of ESAM in atherosclerosis remains unclear. In this study, we assessed the role of ESAM in monocyte/ macarophage infiltration, and examined effects of ESAM inactivation in the development atherosclerosis using a murine model of atherosclerosis. Methods and Results : ESAM−/− mice were bred with apoE−/− mice to generate the double knockout mice, and the lesion size of aortic sinus was evaluated histologically between ESAM+/+ apoE−/− and ESAM−/− apoE+/+ mice. Plasma lipid profile was not affected by ESAM deficiency. However, the lesion size was markedly attenuated in ESAM−/− apoE−/− mice compared to ESAM+/+apoE−/− mice. The percentage of MOMA-2-stained area in the aortic sinus lesions was significantly smaller in ESAM-/-apoE−/− mice than in ESAM+/+apoE−/− mice, suggesting that ESAM deficiency reduced the macrophage infiltration in the atheroma. To clarify the mechanism for the reduced macrophage content in the plaque, in vitro adhesion- and transendothelial migration assays were performed between cultured endothelial monolayers and monocyte/macrophage cell line THP-1 cells utilizing siRNA-mediated knockdown of ESAM. These assays revealed that ESAM deficiency in endothelial cells resulted in decreases in monocyte adhesion to the endothelial cells as well as transendothelialmigration. THP-1 cells did not express ESAM, but directly bound to the recommbinant ESAM protein-coated culture plates. Conclusion : ESAM modulates macrophage infiltration into the atheroma through interaction with unidentified ligand(s) on monocytes. ESAM inactivation can reduce susceptibility to atherosclerosis.
A New Tool for Clinical Neuroscience—Synaptic Imaging
Authors: Elizabeth C. Mormino, William J. Jagust
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Response to “Comment on: ‘When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council’”
Authors: Eric L. Simpson, Nick J. Reynolds, Carsten Flohr, Amy S. Paller, Jonathan I. Silverberg, Michel J. Cork, Emma Guttman-Yassky, Alan D. Irvine
Journal: Journal of the American Academy of Dermatology (2018)
Novel insights on m6A RNA methylation in tumorigenesis: a double-edged sword
Authors: Shaoyun Wang, Peiwei Chai, Ruobing Jia, Renbing Jia
Journal: Molecular Cancer (2018)

N6-methyladenosine (m6A), the most prevalent modification of mammalian RNA, has received increasing attention. Although m6A has been shown to be associated with biological activities, such as spermatogenesis modulation, cell spermatogenesis and pluripotency, Drosophila sex determination, and the control of T cell homeostasis and response to heat shock, little is known about its roles in cancer biology and cancer stem cells. Recent articles have noted that some genes have abnormal m6A expression after tumorigenesis, including genes ABS2, RARA, MYB, MYC, ADAM19 and FOX1. Abnormal changes in the m6A levels of these genes are closely related to tumour occurrence and development. In this review, we summarized the 'dual edge weapon' role of RNA methylation in the tumorigenesis. We discussed RNA methylation could lead to not only tumour progression but also tumour suppression. Moreover, we clarified that the abnormal changes in the m6A enrichment of specific loci contribute to tumour occurrence and development, thereby representing a novel anti-cancer strategy by restoration to balanced RNA methylation in tumour cells.
Structural Basis of Highly Specific Interaction between Nephrin and MAGI1 in Slit Diaphragm Assembly and Signaling
Authors: Zhuangfeng Weng, Yuan Shang, Zeyang Ji, Fei Ye, Lin Lin, Rongguang Zhang, Jinwei Zhu
Journal: Journal of the American Society of Nephrology (2018)

Background The slit diaphragm is a specialized adhesion junction between opposing podocytes, establishing the final filtration barrier that prevents passage of proteins from the capillary lumen into the urinary space. Nephrin, the key structural and signaling adhesion molecule expressed in the slit diaphragm, contains an evolutionally conserved, atypical PDZ-binding motif (PBM) reported to bind to a variety of proteins in the slit diaphragm. Several mutations in NPHS1 (the gene encoding nephrin) that result in nephrin lacking an intact PBM are associated with glomerular diseases. However, the molecular basis of nephrin-PBM–mediated protein complexes is still unclear. Methods Using a combination of biochemic, biophysic, and cell biologic approaches, we systematically investigated the interactions between nephrin-PBM and PDZ domain–containing proteins in the slit diaphragm. Results We found that nephrin-PBM specifically binds to one member of the membrane-associated guanylate kinase family of scaffolding proteins, MAGI1, but not to another, MAGI2. The complex structure of MAGI1-PDZ3/nephrin-PBM reveals that the Gly at the −3 position of nephrin-PBM is the determining feature for MAGI1-PDZ3 recognition, which sharply contrasts with the typical PDZ/PBM binding mode. A single gain-of-function mutation within MAGI2 enabled nephrin-PBM binding. In addition, using our structural analysis, we developed a highly efficient inhibitory peptide capable of specifically blocking the nephrin/MAGI1 interaction. Conclusions MAGI1 interacts with nephrin-PBM with exquisite specificity. A newly developed, potent inhibitory peptide that blocks this interaction may be useful for future functional investigations in vivo . Our findings also provide possible explanations for the diseases caused by NPHS1 mutations.
Response by Glatz et al to Letter Regarding Article, “Comparison Between Patent Ductus Arteriosus Stent and Modified Blalock-Taussig Shunt as Palliation for Infants With Ductal-Dependent Pulmonary Blood Flow: Insights From the Congenital Catheterization Research Collaborative”
Authors: Andrew C. Glatz, Christopher J. Petit, Bryan H. Goldstein, Athar M. Qureshi
Journal: Circulation (2018)